Company / R&D Expense
Mineralys Therapeutics, Inc. R&D Expense History
FY2022-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$168.6M
FY2024
5-year range
$26.3M / $168.6M
FY2022-FY2024
Trend
+139.6%
vs FY2023
Sector context
#95 of 210
Health Care
What the data says
At $169M, Mineralys Therapeutics, Inc.'s r&d expense ranks #95 of 210 in the Health Care sector. Improved from $26M to $169M over the past 2 years.
Based on SEC 10-K filings.
$169M in FY2024.
Improved from $26M to $169M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#95 of 210 in Health CareTop 45% of 210This company $168.6M Sector average $644.1M
▼
-73.8% below sector average
Key checks
Key Insights
- In FY2024, r&d expense increased 139.6% year-over-year.
- Ranks #95 out of 210 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 3.25 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $168.6M | +139.6% |
| FY2023 | $70.4M | +168.0% |
| FY2022 | $26.3M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026